Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Reducing Risk of Fracture in Metastatic CRPC

July 31st 2019

AR-V7 as a Predictive Biomarker in Metastatic CRPC

July 31st 2019

Frontline Therapy in Newly Diagnosed Metastatic HSPC

July 31st 2019

Historical Perspectives on ADT in Prostate Cancer

July 31st 2019

ASCO 2019: Novel Agents in Metastatic CSPC

July 31st 2019

Expanding Treatment Options for Metastatic CSPC

July 31st 2019

Cardiac Toxicity in Nonmetastatic CRPC

July 31st 2019

Management of Adverse Events in M0 CRPC

July 31st 2019

Practical Advice on Follow-Up for Patients with M0 CRPC

July 31st 2019

Benefits of Newly Approved Drugs for M0 CRPC

July 31st 2019

MFS as a Clinical Endpoint in nmCRPC

July 31st 2019

Imaging Utilized in Diagnosis of CRPC

July 31st 2019

Advancements in Nonmetastatic CRPC

July 31st 2019

Dr. Tan Discusses the FDA Approval of Darolutamide in M0CRPC

July 31st 2019

Winston Tan, MD, hematologist/oncologist, Mayo Clinic, discusses the FDA approval of darolutamide (Nubeqa) in nonmetastatic castration-resistant prostate cancer (M0CRPC).

FDA Approves Darolutamide for Nonmetastatic CRPC

July 31st 2019

The FDA has approved darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. Gomella on the Role of PSA in Early Detection of Prostate Cancer

July 30th 2019

Leonard G. Gomella, MD, discusses the role of prostate-specific antigen screening in the early detection of prostate cancer.

Dr. Bradley on Adverse Events Associated With Enzalutamide and Apalutamide in Prostate Cancer

July 26th 2019

Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the adverse events (AEs) that are associated with enzalutamide (Xtandi) and apalutamide (Erleada) in prostate cancer.

Dr. Vaena on Major Advances in Metastatic Prostate Cancer

July 26th 2019

Daniel Vaena, MD, hematologist/medical oncologist and hematologist, West Cancer Center, discusses progress made in the treatment of patients with metastatic prostate cancer.

Dr. Yu on Future Directions in Prostate Cancer

July 25th 2019

Evan Y. Yu, MD, professor, Department of Medical Oncology, University of Washington School of Medicine, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, and clinical trials core director, Genitourinary Medical Oncology, Seattle Cancer Care Alliance, discusses future directions in prostate cancer.

Pivotal Trials Propel Progress in Prostate Cancer

July 24th 2019

Celestia S. Higano, MD, FACP, shares insight on key trials in prostate cancer.